Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Implants / Devices
    • Everstone buys...

    Everstone buys Malaysian medical devices company Chemopharm

    Written by Ruby Khatun Khatun Published On 2017-11-25T10:15:44+05:30  |  Updated On 25 Nov 2017 10:15 AM IST
    Everstone buys Malaysian medical devices company Chemopharm

    MUMBAI: India-focused private equity major Everstone Group has acquired Malaysian medical devices firm Chemopharm - its fourth in the healthcare segment for an undisclosed amount.


    The deal will be carried out via Everlife, the Singapore-headquartered fund said in a statement without offering the deal value.

    The deal is done through a Singaporean partner Cure Capital as a co-investor.

    Everlife is an Everstone platform specially created for the healthcare sector. The acquisition is being funded from the third fund--Everstone Capital Partners, which has a corpus of USD 730 million.

    "Everstone has significant experience in the healthcare sector and this is its fourth investment and (we) will be looking at more opportunities in this space," Everstone Group's managing director Amit Manocha, who is also on the board of Everlife, said.

    Similar to Everlife, it is an investor in a leading domestic pharma distribution platform Ascent and has since been scaled up rapidly.

    Other Everstone investments in the healthcare area are Rubicon, a domestic drug delivery technology company, as well as OmniActive, a supplier of naturally sourced ingredients for eye health, weight management, and heart care.

    In 2015, the fund had exited Global Hospitals, a large multi-specialty tertiary hospital chain.

    Chemopharm is headquartered in Malaysia and has operations in Singapore, Thailand, Indonesia, Vietnam and the Philippines. It is a leading player in the Southeast Asian medical devices/equipment market that is growing at 10 to 15 percent annually.

    Founded in 1976, Chemopharm represents over 50 principals and caters to over 4,000 customers, including hospitals, labs, and research facilities.

    The Everstone Group has assets under management of around USD 4 billion and employs over 200 people across six offices in Singapore, Mumbai, New Delhi, Bengaluru, Mauritius, and London.
    acquireAcquisitionAmit ManochabuysChemopharmEverlifeEverstoneEverstone Capital PartnersEverstone GroupfundGlobal HospitalsHealthcareInvestmentMalaysianMedical DevicesOmniActiveRubicon
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok